{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:11:09Z","timestamp":1794863469468,"version":"4.9.1"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Adenovirus vaccines, particularly the COVID-19 Ad5-nCoV adenovirus vaccine, have emerged as promising tools in the fight against infectious diseases. In this study, we investigated the structure of the T cell response to the Spike protein of the SARS-CoV-2 virus used in the COVID-19 Ad5-nCoV adenoviral vaccine in a phase 3 clinical trial (NCT04540419). In 69 participants, we collected peripheral blood samples at four time points after vaccination or placebo injection. Sequencing of T cell receptor repertoires from Spike-stimulated T cell cultures at day 14 from 17 vaccinated revealed a more diverse CD4<jats:sup>+<\/jats:sup> T cell repertoire compared to CD8<jats:sup>+<\/jats:sup>. Nevertheless, CD8<jats:sup>+<\/jats:sup> clonotypes accounted for more than half of the Spike-specific repertoire. Our longitudinal analysis showed a peak T cell response at day 14, followed by a decline until month 6. Remarkably, multiple T cell clonotypes persisted for at least 6 months after vaccination, as demonstrated by ex vivo stimulation. Examination of CDR3 regions revealed homologous sequences in both CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup> clonotypes, with major CD8<jats:sup>+<\/jats:sup> clonotypes sharing high similarity with annotated sequences specific for the NYNYLYRLF peptide, suggesting potential immunodominance. In conclusion, our study demonstrates the immunogenicity of the Ad5-nCoV adenoviral vaccine and highlights its ability to induce robust and durable T cell responses. These findings provide valuable insight into the efficacy of the vaccine against COVID-19 and provide critical information for ongoing efforts to control infectious diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1369436","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T04:57:49Z","timestamp":1712033869000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Clonal structure and the specificity of vaccine-induced T cell response to SARS-CoV-2 Spike protein"],"prefix":"10.3389","volume":"15","author":[{"given":"Saveliy A.","family":"Sheetikov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra A.","family":"Khmelevskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenia V.","family":"Zornikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan V.","family":"Zvyagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina S.","family":"Shomuradova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yana V.","family":"Serdyuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naina T.","family":"Shakirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iuliia O.","family":"Peshkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksei","family":"Titov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitrii S.","family":"Romaniuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina A.","family":"Shagina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry M.","family":"Chudakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry O.","family":"Kiryukhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga V.","family":"Shcherbakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina G.","family":"Khamaganova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitalina","family":"Dzutseva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Afanasiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apollinariya V.","family":"Bogolyubova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigory A.","family":"Efimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-coV-2 vaccine","volume":"384","author":"Baden","year":"2020","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/s0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-coV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Moderbacher","year":"2020","journal-title":"Cell"},{"key":"B7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0901-9","article-title":"Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19","volume":"26","author":"Liao","year":"2020","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abf3698","article-title":"Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection","volume":"5","author":"Reynolds","year":"2020","journal-title":"Sci Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.immuni.2021.05.010","article-title":"Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease","volume":"54","author":"Bergamaschi","year":"2021","journal-title":"Immunity"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg5021","article-title":"Integrated longitudinal immunophenotypic, transcriptional, and repertoire analyses delineate immune responses in patients with COVID-19","volume":"6","author":"Notarbartolo","year":"2021","journal-title":"Sci Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108728","article-title":"Early induction of functional SARS-CoV-2 specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients","volume":"34","author":"Tan","year":"2021","journal-title":"Cell Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1101\/2020.11.02.20222778","article-title":"SARS-CoV-2 responsive T cell numbers are associated with protection from COVID-19: A prospective cohort study in keyworkers","author":"Wyllie","year":"2021","journal-title":"Medrxiv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.19.21262278","article-title":"A prospective study of the protective effect of SARS-CoV-2\u2013specific antibodies and T cells in Moscow residents","volume":"75","author":"Molodtsov","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"ji2101052","DOI":"10.4049\/jimmunol.2101052","article-title":"Boosting of the SARS-coV-2\u2013specific immune response after vaccination with single-dose sputnik light vaccine","volume":"208","author":"Komissarov","year":"2022","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17877","article-title":"T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid Malignancies","volume":"196","author":"Marasco","year":"2022","journal-title":"Brit J Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac278","article-title":"SARS-CoV-2-specific T cells and antibodies in COVID-19 protection: a prospective study","volume":"75","author":"Molodtsov","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","article-title":"Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19","volume":"21","author":"Peng","year":"2020","journal-title":"Nat Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100204","article-title":"Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases","volume":"2","author":"Tarke","year":"2021","journal-title":"Cell Rep Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.immuni.2020.11.004","article-title":"SARS-coV-2 epitopes are recognized by a public and diverse repertoire of human T cell receptors","volume":"53","author":"Shomuradova","year":"2020","journal-title":"Immunity"},{"key":"B22","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2598-9","article-title":"SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19","volume":"587","author":"Braun","year":"2020","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157699","article-title":"Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2","volume":"7","author":"Titov","year":"2022","journal-title":"JCI Insight"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100092","article-title":"Robust T cell response toward spike, membrane, and nucleocapsid SARS-coV-2 proteins is not associated with recovery in critical COVID-19 patients","volume":"1","author":"Thieme","year":"2020","journal-title":"Cell Rep Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.immuni.2020.10.006","article-title":"Unbiased screens show CD8+ T cells of COVID-19 patients recognize shared epitopes in SARS-CoV-2, most of which are not located in the Spike protein","volume":"53","author":"Ferretti","year":"2020","journal-title":"Immunity"},{"key":"B26","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","article-title":"SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition","volume":"22","author":"Nelde","year":"2020","journal-title":"Nat Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41591-020-01143-2","article-title":"Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells","volume":"27","author":"Schulien","year":"2021","journal-title":"Nat Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"100354","DOI":"10.1016\/j.xcrm.2021.100354","article-title":"Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells","volume":"2","author":"Cohen","year":"2021","journal-title":"Cell Rep Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s42003-022-04250-7","article-title":"Clonal diversity predicts persistence of SARS-CoV-2 epitope-specific T-cell response","volume":"5","author":"Zornikova","year":"2022","journal-title":"Commun Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1070077","article-title":"Architecture of the SARS-CoV-2-specific T cell repertoire","volume":"14","author":"Zornikova","year":"2023","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans","volume":"595","author":"Sahin","year":"2021","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abj1750","article-title":"SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees","volume":"6","author":"Geers","year":"2021","journal-title":"Sci Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/jci149335","article-title":"SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63","volume":"131","author":"Woldemeskel","year":"2021","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1101\/2021.06.21.21259010","article-title":"Emergence of immune escape at dominant SARS-CoV-2 killer T-cell epitope","volume":"185","author":"Dolton","year":"2021","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41467-021-27669-8","article-title":"Structural assessment of HLA-A2-restricted SARS-CoV-2 spike epitopes recognized by public and private T-cell receptors","volume":"13","author":"Wu","year":"2022","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41467-022-34033-x","article-title":"SARS-CoV-2 escape from cytotoxic T cells during long-term COVID-19","volume":"14","author":"Stanevich","year":"2023","journal-title":"Nat Commun"},{"key":"B37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41590-021-01084-z","article-title":"An immunodominant NP105\u2013113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease","volume":"23","author":"Peng","year":"2021","journal-title":"Nat Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41586-021-04186-8","article-title":"Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2","volume":"601","author":"Swadling","year":"2021","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.12482","article-title":"SARS-CoV-2-specific CD8+ T-cell responses and TCR signatures in the context of a prominent HLA-A*24:02 allomorph","volume":"99","author":"Rowntree","year":"2021","journal-title":"Immunol Cell Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"New Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.793102","article-title":"T cells targeting SARS-coV-2: by infection, vaccination, and against future variants","volume":"8","author":"Nguyen","year":"2021","journal-title":"Front Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12979-021-00246-9","article-title":"Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people","volume":"18","author":"Parry","year":"2021","journal-title":"Immun Ageing"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/s2666-7568(21)00169-0","article-title":"Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5\u20136 weeks post vaccine in participants aged 80 years or older: an exploratory analysis","volume":"2","author":"Parry","year":"2021","journal-title":"Lancet Heal Longev"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0278878","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia","volume":"18","author":"Lioznov","year":"2023","journal-title":"PloS One"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1016\/j.cell.2022.05.022","article-title":"Humoral and cellular immune memory to four COVID-19 vaccines","volume":"185","author":"Zhang","year":"2022","journal-title":"Cell"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.12.21267518","article-title":"Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2","volume":"2021","author":"Titov","year":"2021","journal-title":"Medrxiv"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-51964\/v1","article-title":"A large-scale database of T-cell receptor beta (TCR\u03b2) sequences and binding associations from natural and synthetic exposure to SARS-CoV-2","author":"Nolan","year":"2020","journal-title":"Res Square"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-022-01578-0","article-title":"VDJdb in the pandemic era: a compendium of T cell receptors specific for SARS-CoV-2","volume":"19","author":"Goncharov","year":"2022","journal-title":"Nat Methods"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj9853","article-title":"Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells","volume":"374","author":"Mateus","year":"2021","journal-title":"Science"},{"key":"B51","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron","volume":"185","author":"Tarke","year":"2022","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04460-3","article-title":"T cell responses to SARS-CoV-2 spike cross-recognize Omicron","volume":"603","author":"Keeton","year":"2022","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl5344","article-title":"BNT162b2 vaccination induces durable SARS-CoV-2 specific T cells with a stem cell memory phenotype","volume":"6","author":"Guerrera","year":"2021","journal-title":"Sci Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.153201","article-title":"Single-cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine","volume":"6","author":"Sureshchandra","year":"2021","journal-title":"JCI Insight"},{"key":"B55","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41421-021-00300-2","article-title":"Integrated single-cell analysis revealed immune dynamics during Ad5-nCoV immunization","volume":"7","author":"Cao","year":"2021","journal-title":"Cell Discovery"},{"key":"B56","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-021-03681-2","article-title":"Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans","volume":"596","author":"Alter","year":"2021","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-022-01106-y","article-title":"SARS-CoV-2-specific T-cell epitope repertoire in convalescent and mRNA-vaccinated individuals","volume":"7","author":"Lang-Meli","year":"2022","journal-title":"Nat Microbiol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104048","article-title":"SARS-CoV-2 vaccination diversifies the CD4+ spike-reactive T cell repertoire in patients with prior SARS-CoV-2 infection","volume":"80","author":"Dykema","year":"2022","journal-title":"eBioMedicine"},{"key":"B59","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/s41590-022-01184-4","article-title":"SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells","volume":"23","author":"Minervina","year":"2022","journal-title":"Nat Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1035344","article-title":"Three doses of BNT162b2 COVID-19 mRNA vaccine establish long-lasting CD8+ T cell immunity in CLL and MDS patients","volume":"13","author":"Hernandez","year":"2023","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1016\/j.cell.2022.07.002","article-title":"Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope","volume":"185","author":"Dolton","year":"2022","journal-title":"Cell"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/leu.2016.321","article-title":"Tracking T-cell immune reconstitution after TCR\u03b1\u03b2\/CD19-depleted hematopoietic cells transplantation in children","volume":"31","author":"Zvyagin","year":"2016","journal-title":"Leukemia"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3364","article-title":"MiXCR: software for comprehensive adaptive immunity profiling","volume":"12","author":"Bolotin","year":"2015","journal-title":"Nat Methods"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2960","article-title":"Towards error-free profiling of immune repertoires","volume":"11","author":"Shugay","year":"2014","journal-title":"Nat Methods"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004503","article-title":"VDJtools: unifying post-analysis of T cell receptor repertoires","volume":"11","author":"Shugay","year":"2015","journal-title":"PloS Comput Biol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00251-005-0781-7","article-title":"The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage","volume":"57","author":"Nielsen","year":"2005","journal-title":"Immunogenetics"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1369436\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T04:57:55Z","timestamp":1712033875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1369436\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":66,"alternative-id":["10.3389\/fimmu.2024.1369436"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1369436","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2024.1369436.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2024.1369436.s002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2024.1369436.s003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2024.1369436.s004","asserted-by":"subject"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,2]]},"article-number":"1369436"}}